One of the FDA’s initiatives for 2021 is to streamline the 510(k) pathways, allowing more efficient access to new medical technologies. Part of this streamlining is enhancing the Safety and Performance Based Pathway, which is an alternative route to traditional 510(k) clearance aimed at moderate-risk devices. With this pathway, a medical device firm would only need to demonstrate that their device meets the FDA’s established safety and performance criteria and would not need to provide a direct testing comparison to a predicate device...